Your Patients Need Help Finding Their Insulin

The phone calls are piling up. Your inbox has messages from worried patients. The story is always the same: "My pharmacy doesn't have my insulin. What do I do?"

As a prescriber, you're already stretched thin. But the Insulin Aspart shortage has made medication access a front-line clinical issue. Patients who can't get their mealtime insulin are at risk for hyperglycemia, DKA, and hospitalization — all of which are preventable with a little proactive planning.

This guide gives your practice concrete, actionable steps to help patients navigate the shortage efficiently.

Current Availability: What's In Stock and What's Not

As of early 2026, the Insulin Aspart supply picture looks like this:

• Discontinued (no longer manufactured):
  • NovoLog 10 mL vials
  • NovoLog 3 mL FlexPens
  • NovoLog 3 mL PenFill cartridges
• Available but supply may vary:
  • NovoLog FlexTouch pens
  • Fiasp FlexTouch pens and vials
• New to market (availability growing):
  • Kirsty (insulin aspart-xjhz) — interchangeable biosimilar
  • Merilog (insulin aspart-szjj) — biosimilar
• No shortage (therapeutic alternatives):
  • Insulin Lispro (Humalog, Admelog, Lyumjev)
  • Insulin Glulisine (Apidra)

For the detailed shortage timeline and background, see our clinical briefing on the Insulin Aspart shortage.

Why Patients Can't Find Their Insulin

Patients face multiple barriers beyond simple stock-outs:

• Prescription-form mismatch — Prescriptions written for discontinued forms (vials, FlexPens, PenFill) result in fill failures. The pharmacy can't dispense what doesn't exist.
• Formulary confusion — Some patients don't know their insurance may prefer a different rapid-acting insulin or biosimilar. They're told it's "not covered" and interpret that as "not available."
• Chain pharmacy bottlenecks — High-volume chain pharmacies deplete limited supply faster. Patients who only go to one pharmacy may assume the drug is unavailable everywhere.
• Biosimilar awareness gap — Many patients haven't heard of Kirsty or Merilog and are hesitant to accept a substitution they don't understand.

What Providers Can Do: 5 Steps

Step 1: Audit Active Prescriptions for Discontinued Forms

Run a report of patients on Insulin Aspart. Any prescriptions specifying NovoLog vials, FlexPens, or PenFill cartridges need to be updated immediately to a currently available form:

• NovoLog FlexTouch
• Fiasp FlexTouch or vial
• Kirsty (insulin aspart-xjhz)
• Merilog (insulin aspart-szjj)

This one step alone will prevent many pharmacy-level fill failures.

Step 2: Educate Patients About Biosimilars

Many patients are wary of anything that sounds "different" from what they've been taking. A brief conversation can make the difference:

• "Kirsty is the same insulin with a different brand name. The FDA confirmed it works identically to NovoLog. Your pharmacist can fill your prescription with it directly."
• "Merilog is also the same insulin, made by a different company. We'd need to update your prescription, but the medication itself is equivalent."

Consider adding a note in patient after-visit summaries about biosimilar equivalence.

Step 3: Direct Patients to Medfinder

Medfinder for Providers shows real-time pharmacy stock data for Insulin Aspart. You can:

• Send patients the link so they can check availability before going to the pharmacy
• Have your front desk staff search Medfinder when patients call about fill failures
• Include the Medfinder URL in patient instructions and after-visit summaries

This reduces call volume to your office and helps patients take action quickly.

Step 4: Pre-Authorize Alternative Insulins

For patients who may face ongoing supply issues, consider writing a backup prescription for a therapeutic alternative:

• Insulin Lispro (generic or Humalog) — widely available, no current shortage, 1:1 dose conversion
• Insulin Glulisine (Apidra) — another option if lispro is also constrained on the patient's formulary

Include a note in the chart explaining the switch rationale. This way, if Insulin Aspart becomes unavailable again, the patient has a ready alternative without needing to contact your office urgently.

Step 5: Connect Patients With Cost Resources

For patients facing cost barriers in addition to supply issues:

• NovoCare Savings Card — copays as low as $25 for commercially insured patients (novocare.com)
• Novo Nordisk PAP — free insulin for qualifying uninsured patients (income ≤400% FPL)
• $35/month Medicare cap — under the Inflation Reduction Act
• GoodRx/SingleCare — generic insulin aspart as low as $74 per vial

Share our patient-facing guide: How to save money on Insulin Aspart in 2026.

Alternatives to Insulin Aspart: Quick Reference

When a switch is needed, here's a quick-reference comparison:

• Insulin Lispro (Humalog/Admelog/Lyumjev) — Onset: 15-30 min, Peak: 1-2 hr, Duration: 3-5 hr. 1:1 conversion. Most widely available rapid-acting insulin.
• Insulin Glulisine (Apidra) — Onset: 15-30 min, Peak: 1-2 hr, Duration: 3-5 hr. 1:1 conversion. Less commonly prescribed but no supply issues.
• Kirsty (insulin aspart-xjhz) — Interchangeable biosimilar. Same as NovoLog. Pharmacy can substitute.
• Merilog (insulin aspart-szjj) — Biosimilar. Same as NovoLog. Prescription update may be needed.

For details, see our guide to Insulin Aspart alternatives.

Workflow Tips for Your Practice

• Create a shortage response protocol — define who handles patient calls about supply issues, what scripts to use, and when to escalate to the prescriber
• Batch prescription updates — don't wait for patients to call; proactively update prescriptions for patients on discontinued forms
• Add Medfinder to your patient handouts — medfinder.com/providers
• Set up EMR alerts — flag patients on Insulin Aspart for proactive outreach during supply disruptions
• Coordinate with local pharmacies — establish relationships with 2-3 pharmacies (including independents) that can serve as backup sources during shortages

Final Thoughts

The Insulin Aspart shortage is a temporary — but serious — challenge. The good news is that the tools exist to manage it. Proactive prescription management, patient education, and resource sharing can keep your patients safe and their blood sugar controlled while the market adjusts.

For additional clinical context, read our full clinical briefing on the shortage. For guidance on helping patients manage costs, see the provider's guide to helping patients save money on Insulin Aspart.